Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Simlukafusp alfa

Catalog #:   DHG32202 Specific References (7) DATASHEET
Host species: Human
Isotype: IgG1-kappa
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DHG32202

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

Surface-expressed protease, Gelatine degradation protease FAP, Integral membrane serine protease, Dipeptidyl peptidase FAP, Seprase, FAP, Post-proline cleaving enzyme, APCE, SIMP, FAPalpha, 170 kDa melanoma membrane-bound gelatinase, Fibroblast activation protein alpha, Serine integral membrane protease, Prolyl endopeptidase FAP

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q12884

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

Simlukafusp alfa

Data Image
  • Bioactivity
    Detects FAP/FAPalpha in indirect ELISAs.
References

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma., PMID:39895413

Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma., PMID:39422604

Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma., PMID:39395231

Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors., PMID:39140264

Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer., PMID:38709220

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors., PMID:38630781

Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy., PMID:33974508

Datasheet
$ 484
Product specifications
100 μg 484 1 mg 1932

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Simlukafusp alfa [DHG32202]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only